Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
- CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its management team will host a company event at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL and will participate in the Jefferies 2025 Global Healthcare Conference, being held June 3-5, 2025 in New York, NY.
- 05/29/2025
|
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
- CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who have received prior therapy. These data will be presented on Sunday, June 1 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as an oral presentation during the “Lung Cancer – Non-Small Cell Metastatic” session from 9:00 AM-9:12 AM CDT (Abstract #8503).
- 05/22/2025
|
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
- Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025
- 05/08/2025
|
Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know
- The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 292.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- 05/01/2025
|
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United States
- CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases Sjögren's disease represents the third indication under development for CLN-978, and is a disease with high unmet need and no currently approved therapies CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the Company is initiating a study of CLN-978 in patients with Sjögren's disease (SjD) in the U.S. The Company previously received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) Application clearance to study the CD19 T cell engager in patients with moderate to severe systemic lupus erythematosus (SLE) and European Medicines Agency (EMA) approval to study CLN-978 in active, difficult-to-treat rheumatoid arthritis.
- 04/29/2025
|
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
- Cullinan and Taiho previously announced the Phase 2b portion of the study met the primary endpoint of overall response rate Cullinan and Taiho previously announced the Phase 2b portion of the study met the primary endpoint of overall response rate
- 04/23/2025
|
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
- Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025
- 04/16/2025
|
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
- Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U.S. Zipalertinib pivotal Phase 2b study met primary endpoint; full results mid-year 2025 and NDA submission planned H2 2025, pending regulatory discussions Cash and investments of $606.9 million as of December 31, 2024, continues to provide runway into 2028 CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the fourth quarter and full year ended December 31, 2024.
- 02/27/2025
|
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D.
- 02/24/2025
|
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy
- TOKYO, PRINCETON, N.J. and CAMBRIDGE, Mass.
- 01/28/2025
|
Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC
- Cullinan Therapeutics focuses on unaddressed or unmet needs in oncology and autoimmune conditions. In particular, Zipalertinib and CLN-978 stand out as its most promising product candidates. Zipalertinib targets a tiny niche in the large NSCLC market. Management expects to report its Phase 2b results by mid-2025. Similarly, CLN-978 is a first-in-class T-cell engager targeting SLE and RA. It can also potentially be expanded into other B-cell-mediated indications eventually.
- 01/09/2025
|
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline
- Cullinan Therapeutics is a multifocal biotech with promising programs in precision medicine and immunotherapy, despite recent market sentiment declines. Zipalertinib shows potential in treating exon 20 insertion mutation-positive NSCLC, with a 40% objective response rate in early phase trials. CGEM has a strong financial position with cash reserves projected to fund operations into 2028, reducing the need for immediate equity raises.
- 01/08/2025
|
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
- Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases
- 11/14/2024
|
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
- CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference, being held in New York on November 18 and 19, 2024.
- 11/05/2024
|
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
- CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced the upcoming presentation of preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, at American College of Rheumatology (ACR) Convergence 2024, taking place in Washington, D.C. from November 14-19, 2024.
- 11/04/2024
|
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
- CLN-978 is the first development stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company's Investigational New Drug (IND) Application for CLN-978 and its global Phase 1 clinical trial may proceed in the U.S. to assess CLN-978 in patients with moderate to severe systemic lupus erythematosus (SLE).
- 10/16/2024
|
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
- Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic lupus erythematosus
- 09/17/2024
|
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
- Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations treated with zipalertinib who progressed on or after prior amivantamab treatment
- 09/14/2024
|
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the following upcoming investor conferences:
- 08/28/2024
|
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
- Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatment Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatment
- 06/01/2024
|
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
- CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, being held virtually on May 28 and 29, 2024.
- 05/24/2024
|
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
- Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer (NSCLC) with oncogenic mutations
- 05/23/2024
|
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting
- 05/15/2024
|
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
- CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29.
- 04/29/2024
|
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
- CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors.
- 04/24/2024
|
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
- CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication
- 04/16/2024
|
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
- Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 Cullinan to host a virtual investor event on April 16 at 8:00 am ET CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into a stock purchase agreement with certain institutional and accredited investors for a private placement of approximately $274.0 million of shares of its common stock at a price of $19.00 per share and, in lieu of common stock to certain investors, $6.0 million of pre-funded warrants to purchase shares of its common stock at a price of $18.999 per pre-funded warrant.
- 04/16/2024
|
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma
- 03/14/2024
|
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
- Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies
- 03/01/2024
|
Cullinan Oncology to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences:
- 02/27/2024
|
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 in San Francisco, CA. Mr. Ahmed's presentation is scheduled for Thursday, January 11, at 10:30 am PST (1:30 pm EST).
- 12/18/2023
|
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
- CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial. This is a first-in-human, multi-center, open label study designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CLN-617 alone and in combination with pembrolizumab, a programmed death receptor-1 (PD-1) targeted checkpoint inhibitor, in patients with advanced solid tumors.
- 12/14/2023
|
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024
- 11/08/2023
|
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
- Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting Preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, supports proposed mechanism of action and demonstrates that the observed monotherapy clinical activity was seen in patients with tumors not typically responsive to checkpoint inhibitor therapy Data highlight progress of Cullinan's diverse pipeline including CLN-619, an anti-MICA/B antibody; CLN-418, a B7H4X4-1BB-bispecific immune activator; CLN-978, a CD19XCD3 bispecific T cell engager; and CLN-617, a fusion protein harnessing IL-2 and IL-12 cytokines CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that it will present data across four distinct immuno-oncology programs in five poster presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting taking place November 1-5 in San Diego.
- 11/03/2023
|
Cullinan Oncology to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences:
- 10/30/2023
|
Cullinan Oncology: Inexplicably Trading Below Cash Despite Robust Data
- Cullinan Oncology's stock remains below cash value despite positive phase 1 trial data for its second asset, CLN-619. The company's lead asset, Zipalertinib, has shown promising results in treating EGFRex20ins NSCLC, positioning it as a potential treatment of choice in this patient population. Cullinan Oncology has initiated a phase 3 study for Zipalertinib and has released encouraging data for its second candidate, CLN-619, in heavily pretreated patients.
- 09/11/2023
|
Cullinan Oncology to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences:
- 09/06/2023
|
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer (NSCLC) patients (REZILIENT-3) open to enrollment
- 08/10/2023
|
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating CLN-978 for the treatment of relapsed/refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL).
- 08/09/2023
|
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
- Phase 3 trial will assess progression-free survival of zipalertinib plus chemotherapy versus chemotherapy in adult patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR exon 20 insertion mutations PRINCETON, N.J. and CAMBRIDGE, Mass.
- 08/03/2023
|
Cullinan Oncology to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences:
- 07/31/2023
|
Why Shares of Cullinan Oncology Jumped This Week
- Cullinan Oncology's lead therapy is zipalertinib, which is in a trial to treat non-small cell lung cancer. The company has a deep pipeline and published encouraging news regarding preclinical candidate CLN-619 as a pan-cancer treatment.
- 06/09/2023
|
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
- CLN-619 demonstrated monotherapy activity across a range of tumor types, including in patients whose cancer had progressed on checkpoint inhibitor therapy
- 05/25/2023
|
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
- CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first clinical data from its Phase 1 clinical study of CLN-619 in patients with advanced solid tumors will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from June 2-6.
- 04/26/2023
|
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
- CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial clinical data from the ongoing trial is on-track to be released mid-2023.
- 03/14/2023
|
Cullinan Oncology to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that its management team will participate in the following investor conferences.
- 11/01/2022
|
Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years
- Shares have fallen by 40% since 2021 IPO was priced. I like management's unique approach of focusing on high-impact targets first and then determining the optimal modality after.
- 09/22/2022
|
Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
- Cullinan Oncology's total cash and short-term investment is $611 million, up 94% from the previous quarter. The company's portfolio consists of eight product candidates that can significantly improve the quality of life of patients suffering from various types of cancer.
- 09/14/2022
|
Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference
- CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that Company management will participate in the following investor conferences:
- 09/07/2022
|
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
- CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Financial Officer, Jeff Trigilio, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 in Miami, FL and virtually.
- 05/19/2022
|
Why Are Cullinan Oncology Shares Rising Today?
- Taiho Pharmaceutical Co Ltd will co-develop and co-commercialize Cullinan Oncology Inc (NASDAQ: CGEM) lead program, CLN-081/TAS6417. Under the agreement, Taiho will acquire Cullinan Oncology's subsidiary, Cullinan Pearl, which has worldwide rights outside of Japan to CLN-081/.
- 05/12/2022
|
Cullinan Oncology to Present at the Barclays Global Healthcare Conference
- CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced that it will be participating in the Barclays Healthcare Conference, being held in Miami, FL, March 15-17, 2022.
- 03/09/2022
|
Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022
- Five abstracts selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
- 03/08/2022
|
Cullinan Oncology to Present at SVB Leerink's 11th Annual Global Healthcare Conference
- CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will be participating in SVB Leerink's 11th Annual Global Healthcare Conference, being held virtually February 14-18, 2022.
- 02/07/2022
|
Cullinan Oncology Stock (CGEM): Why The Price Increased
- The stock price of Cullinan Oncology Inc (NASDAQ: CGEM) increased by 1.58% in the most recent trading session. This is why it happened.
- 01/05/2022
|
Cullinan Oncology Posts Updated Data for CLN-081 in NSCLC EGFR Exon 20 Patients
- Cullinan Oncology Inc (NASDAQ: CGEM) reported updated data from its ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patients. The trial includes patients whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations that have progressed on or after prior therapy.
- 12/16/2021
|
Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer
- Ahmed's appointment brings broad development and operational leadership experience to Cullinan, reflecting the advancement of its pipeline and transition to a later-stage oncology company Ahmed's appointment brings broad development and operational leadership experience to Cullinan, reflecting the advancement of its pipeline and transition to a later-stage oncology company
- 10/18/2021
|
Cullinan Oncology to Participate in Upcoming Investor Conferences
- CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced its participation in the following upcoming investor conferences:
- 09/08/2021
|
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
- Follow-up Cullinan Pearl data from Phase 1 portion of ongoing trial showed increased disease control rate (DCR) of 92% in the 100mg dose cohort
- 08/10/2021
|
Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development
- Cullinan is building a unique hub-and-spoke business model in drug development to build more efficient and scalable pipelines. The company has already built out a pipeline of 7 assets and got the model off the ground to prove that they can structure their pipeline based on opportunistic deals.
- 06/30/2021
|
Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data
- Cullinan Oncology (CGEM) is developing its sole pipeline candidate, CLN-081, as a potential treatment for lung cancer in a phase I/IIa study.
- 06/07/2021
|
Why Cullinan Oncology Stock Is Skyrocketing Today
- The company announced encouraging clinical data for its experimental lung cancer drug.
- 06/04/2021
|
Cullinan Oncology Announces Management Transition
- CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that Jon Wigginton, M.D. is stepping down from his day-to-day role as Chief Medical Officer, and will assume the role of Chairman of the company's Scientific Advisory Board (SAB) and Senior Advisor to the CEO.
- 05/21/2021
|
Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021
- CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced that it will provide a clinical update on CLN-081 during a webinar on Friday, June 4th, 2021 at 10:30 am ET (“Pearl Clinical Update Webinar”).
- 05/19/2021
|
Cullinan Oncology Reports First Quarter 2021 Financial Results
- Continued advancement of broad portfolio, highlighted by initiation of Phase 2a dose expansion of Cullinan Pearl in NSCLC patients with EGFRex20ins mutations
- 05/14/2021
|
Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference
- CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) announced today that the company's Chief Financial Officer, Jeff Trigilio, will present at the upcoming 20th Annual Needham Virtual Healthcare Conference.
- 04/07/2021
|
Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights
- Pipeline Progress: Clinical and preclinical programs continue to advance, with encouraging initial Cullinan Pearl data and additional INDs to be filed in 2021 for immuno-oncology assets Cullinan Florentine and Cullinan MICA
- 03/30/2021
|
Cullinan Management, Inc. Announces Business Update
- February 22, 2021
- 02/22/2021
|
U.S. IPO Week Ahead: Canadian IT And German Chemicals Lead A Diverse 9-IPO Week
- U.S. IPO Week Ahead: Canadian IT And German Chemicals Lead A Diverse 9-IPO Week
- 01/30/2021
|
Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
- CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cullinan Management, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, today announced the closing of its initial public offering of 13,685,000 shares of its common stock, including 1,785,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $21.00 per share. The gross proceeds of the offering were $287.4 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Select Market on January 8, 2021 under the symbol “CGEM.” All shares in the offering were offered by Cullinan Management.
- 01/12/2021
|
U.S. IPO Weekly Recap: The New Year Kicks Off With 2 Biotech IPOs And A Tidal Wave Of SPACs
- U.S. IPO Weekly Recap: The New Year Kicks Off With 2 Biotech IPOs And A Tidal Wave Of SPACs
- 01/09/2021
|
